BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12845361)

  • 1. Hormone replacement therapy and the risk of breast cancer: assessment of therapy acceptance in a cohort of previously treated breast cancer patients.
    Anelli A; Gimenez DL; Rocha AP; de Abreu CM; Freitas HC
    Rev Hosp Clin Fac Med Sao Paulo; 2003; 58(2):91-6. PubMed ID: 12845361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for hormone replacement therapy after breast cancer?
    Kwan K; Ward C; Marsden J
    J Br Menopause Soc; 2005 Dec; 11(4):140-4. PubMed ID: 16354457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Breast Cancer - Specifics of Gynecological Care and Counseling].
    Weinberger V; Zikán M
    Klin Onkol; 2016; 29 Suppl 3():S7-15. PubMed ID: 28118719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen versus toremifene in the adjuvant treatment of breast cancer.
    Holli K;
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S37-8. PubMed ID: 12409068
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hormone replacement therapy in menopausal women previously treated for breast cancer].
    This P
    Presse Med; 1996 Feb; 25(4):141-4. PubMed ID: 8728897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
    Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW
    Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Additional effect of SERM: mammary gland].
    Kurebayashi J
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
    Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hormone therapy and breast cancer: a review].
    Lucchi-Angellier E
    Rev Med Interne; 2001 Dec; 22(12):1213-24. PubMed ID: 11794892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy and estrogen-dependent cancers.
    Birkhäuser M
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():99-114. PubMed ID: 7874193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
    Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
    J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.